- Canaccord Genuity says its rating (BUY/$85) on Radius Health (RDUS -2.2%) makes sense because its osteoporosis drug TYMLOS (abaloparatide) has a better risk/benefit profile than Amgen (NASDAQ:AMGN)'s romosozumab which means the latter should not present a credible challenge to TYMLOS uptake. It adds that the FDA could reject romosozumab outright due to its cardiovascular risks (Amgen just received a CRL and will have to include data from the ARCH study in its resubmission).
- Another positive for Radius is RAD-1901 (elacestrant) in breast cancer. Early-stage study results are encouraging.
- Previously: FDA rejects Amgen's marketing application for osteoporosis candidate romosozumab; resubmission to include ARCH and BRIDGE data (July 17)
- Previously: Late-stage extension study confirms long-term treatment effect of Radius Health's TYMLOS; shares up 3% after hours (May 24)
- Source: Briefing.com
- Now read: An Upcoming Conversation With An Expert: Understanding Osteoporosis And Treatment With TYMLOS, Plus ACTIVExtend Results
Original article